A dual targeting novel combination therapy for childhood brain tumours
Background
Brain cancers are one of the most common causes of death in Australians aged 25 and under. There are many subtypes of brain cancer, the most common in children being medulloblastoma whereas the most aggressive is Diffuse intrinsic pontine glioma (DIPG) which has a 5-year survival of less than 1%. Unfortunately, there are a lack of effective drugs for childhood brain tumours and there is an urgent need to identify new therapies.
About the project
High levels of certain proteins, known as c-Myc and MYCN oncoproteins, are associated with poorer outcomes in childhood brain tumours. Associate Professor Cheung and her team are investigating a number of novel compounds that improve the efficacy of an existing type of anti-cancer drug, known as HDAC inhibitors, which target these high levels of oncoproteins. By targeting the specific drivers of childhood brain cancers, this project aims to develop a safer and more effective approach to treating these children.
Impact
This project aims to determine the efficacy of this novel treatment strategy and provide the evidence needed for a follow-on international clinical trial for childhood brain cancers. By combining this new treatment strategy with existing therapies, such as chemotherapy and radiotherapy, the researchers hope to improve outcomes in children living with brain cancer.